Search results for: cell
#35973806 
2022/08/16
To Up
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
Type-I interferons (IFNs-I) have potent antiviral effects. IFNs-I are also overproduced in patients with systemic lupus erythematosus (SLE). Autoantibodies (AAbs) neutralising IFN-α, IFN-β and/or IFN-Ï subtypes are strong determinants of hypoxemic COVID-19 pneumonia, but their impact on inflammation remains unknown.Alexis Mathian, Paul Breillat, Karim Dorgham, Paul Bastard, Caroline Charre, Raphael Lhote, Paul Quentric, Quentin Moyon, Alice-Andrée Mariaggi, Suzanne Mouries-Martin, Clara Mellot, François Anna, Julien Haroche, Fleur Cohen-Aubart, Delphine Sterlin, Noël Zahr, Adrian Gervais, Tom Le Voyer, Lucy Bizien, Quentin Amiot, Micheline Pha, Miguel Hié, Francois Chasset, Hans Yssel, Makoto Miyara, Pierre Charneau, Pascale Ghillani-Dalbin, Jean-Laurent Casanova, Flore Rozenberg, Zahir Amoura, Guy Gorochov
2151 related Products with: Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
500 tests25 mg25 mg100 g48 assays 500 tests96 tests400Tests
Related Pathways
#35973803 2022/08/16
To Up
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
A regulatory T cell (Treg) insufficiency due to shortage of interleukin-2 (IL-2) is central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a multicentre, double-blinded, randomised, placebo-controlled phase II proof-of-concept trial to evaluate the efficacy of low-dose IL-2 therapy in patients with SLE having moderate-to-severe disease activity while receiving standard treatment.Jens Y Humrich, Patrice Cacoub, Michelle Rosenzwajg, Fabien Pitoiset, Hang Phuong Pham, Joel Guidoux, David Leroux, Thomas Vazquez, Gabriela Riemekasten, Josef S Smolen, George Tsokos, David Klatzmann
2737 related Products with: Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
10 mg100.00 ug1 mg500 100.00 ug 0.1 mg 1 mg100ug Lyophilized100.00 ug200ul500 100.00 ug
Related Pathways
#35973802 2022/08/16
To Up
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
We investigated whether soluble immune checkpoints (sICPs) predict treatment resistance, relapse and infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).Gabriele Gamerith, Finn Mildner, Peter A Merkel, Kristina Harris, Laura Cooney, Noha Lim, Robert Spiera, Philip Seo, Carol A Langford, Gary S Hoffman, E William St Clair, Fernando C Fervenza, Paul Monach, Steven R Ytterberg, Duvuru Geetha, Arno Amann, Dominik Wolf, Ulrich Specks, John H Stone, Andreas Kronbichler
1101 related Products with: Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
5 G1-99 mg/ml/ea price x 211-99 mg/ml/ea price x 296T
Related Pathways
#35973774 2022/07/06
To Up
Bioactivity of mefentrifluconazole against different Fusarium spp.
Emergence and development of resistance to 14α-demethylase inhibitors (DMIs) have become a critical issue in both agriculture and medical fields. Mefentrifluconazole, the first isopropanol triazole fungicide belonging to a new subclass of DMIs, has been proposed to show high activity, minimal adverse side effects, and inconsistent cross resistance with other DMIs due to its high structural flexibility. In this study, mefentrifluconazole showed disparate inhibitory activity against the mycelium growth of seven tested Fusarium species. The most sensitive species included F. oxysporum, F. proliferatum, F. commuae, and F. fujikuroi, followed by F. equiseti and F. graminearum, while F. solani was most insensitive. Consistently, mefentrifluconazole presented the strongest inhibiting effects on conidium germination, cell membrane integrity, and ergosterol biosynthesis in F. fujikuroi, followed by F. graminearum, while F. solani ranked last. Further results indicated that all F. fujikuroi isolates causing rice bakanae disease (RBD) were sensitive to mefentrifluconazole regardless of their resistance to prochloraz, tebuconazole, carbendazim, and phenamacril. Additionally, the inoculation tests found that mefentrifluconazole presented a better protective efficacy on rice seedlings when applied 12 h before the F. fujikuroi inoculation, compared to applied 12 h post the inoculation. Overall, this study demonstrated the various bioactivity of mefentrifluconazole combating Fusarium spp. and put new insights into RBD management as well as the applications of DMIs.Yahui Liu, Tianling Ma, Yi Dong, Chenxin Mao, Jianyan Wu, Chuanqing Zhang
2179 related Products with: Bioactivity of mefentrifluconazole against different Fusarium spp.
3x 500 ml50 ug100ug Lyophilized5ug100ug Lyophilized 500 ml 100ug Lyophilized100ug Lyophilized10 ug 1000 ml 100ug Lyophilized
Related Pathways
#35973768 2022/07/22
To Up
Activating transcription factor 2 (AccATF2) regulates tolerance to oxidative stress in Apis cerana cerana.
Activating transcription factor 2 (ATF2), a basic leucine zipper (bZIP) transcription factor, plays a crucial role in immune and DNA damage response in mammals. However, the function of ATF2 in insects remains unknown. Here, we isolated the ATF2 gene from Apis cerana cerana (AccATF2) and found that AccATF2 was a main regulator of the honeybee response to oxidative stress. Our results showed that AccATF2 was highly expressed in the head, thorax and integument. AccATF2 was expressed throughout the development period of honeybees, and the highest AccATF2 transcript level was noted in brown-eyed pupae, indicating its indispensable roles in honeybee survival. Antioxidant function analysis showed that AccATF2 expression was markedly induced in response to oxidative stress caused by various environmental stresses. AccATF2 overexpression substantially enhanced the tolerance to oxidative stress of Escherichia coli cells compared with control cells. AccATF2 knockdown significantly increased the production of malondialdehyde (MDA), the transcription of antioxidant genes and the activity of antioxidant enzymes in honeybees, suggesting that AccATF2 knockdown resulted in oxidative damage to honeybees. Moreover, AccATF2 knockdown decreased honeybee resistance to oxidative stress caused by high temperature. Overall, AccATF2 plays an important role in maintaining redox homeostasis and protecting honeybees from oxidative stress caused by various environmental stimuli. Our discoveries add to a growing understanding of how honeybees cope with various adverse environmental conditions to ensure their survival.Lijun Wang, Jiayu Wang, Huijuan Guo, Ying Wang, Baohua Xu, Xingqi Guo, Chen Wang